Home > Oncology > ELCC 2022 > Lung Cancer Epidemiology > Rare EGFR mutations as oncogenic drivers

Rare EGFR mutations as oncogenic drivers

Presented By
Dr Alfredo Addeo (University Hospital of Geneva, Switzerland) and Dr Giulia Pasello (Veneto Institute of Oncology, Italy)
Presented by
Alfredo Addeo University Hospital of Geneva, Switzerland
Conference
ELCC 2022
Doi
https://doi.org/10.55788/1439503a
In an educational session, Dr Alfredo Addeo (University Hospital of Geneva, Switzerland) and Dr Giulia Pasello (Veneto Institute of Oncology, Italy) overviewed rare EGFR mutations as oncogenic drivers of lung cancer and (emerging) strategies to target these mutations. Dr Addeo focused on EGFR exon 20 insertions, a heterogeneous group of mutations predominantly found between amino acids 766 and 775 of exon 20. The prevalence of EGFR exon 20 insertions in non-small cell lung cancer (NSCLC) is about 1.5% (4–10% of all EGFR mutations in lung cancer) and treatment outcomes for patients with EGFR exon 20 insertions are less favourable than those of patients with other EGFR mutations [1,2]. This is because the EGFR exon 20 insertions induce clinical resistance for the majority of standard tyrosine kinase inhibitor treatment options like erlotinib or gefitinib. This resistance is due to a conformation...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on